A new ASRM review found no high-quality evidence that “restorative reproductive medicine” matches IVF — yet it is being sold as a replacement. Here is what the numbers actually show, and what a lost year can cost.
A 38-year-old sits across from me. She has been trying to get pregnant for three years. A friend told her about “restorative reproductive medicine” — treat the real problem, skip IVF, let the body do what it was built to do. She wants to know if she should try it first. It is a fair question. It deserves an honest answer, not a sales pitch from either side.
Restorative reproductive medicine, or RRM, is an approach that says: do not bypass the reproductive system — find what is broken and fix it.
Chart the menstrual cycle. Look for endometriosis, polycystic ovary syndrome, thyroid trouble, ovulation problems, hormone problems. Treat those, then let conception happen on its own. Its best-known brand is NaProTechnology, built around a cycle-charting system. In the last two years RRM has jumped from the clinic into politics, promoted as an alternative to in vitro fertilization (IVF), especially by groups that object to how IVF creates and discards embryos.
Here is what RRM actually involves:
Cycle charting (fertility awareness–based methods): Daily tracking of biomarkers — usually cervical mucus, sometimes basal body temperature or hormone test strips — most often with the Creighton Model FertilityCare System. This is the backbone of the approach and guides the timing of every test and treatment.
Targeted diagnostic workup: A search for the underlying cause rather than moving straight to IVF — cycle-timed hormone panels (progesterone, estradiol, LH, prolactin, thyroid), ultrasound monitoring of follicle growth and ovulation, and evaluation for endometriosis, polycystic ovary syndrome (PCOS), luteal phase deficiency, and male-factor problems.
Medical treatment of what is found: Ovulation induction (letrozole or clomiphene), luteal-phase progesterone support, thyroid correction, treatment of low or high prolactin, and treatment of infection or inflammation.
Surgical treatment (”NaProTechnology surgery”): Laparoscopic excision of endometriosis, lysis of pelvic adhesions, and removal or repair of polyps, fibroids, or tubal disease to restore normal pelvic anatomy.
Lifestyle and nutritional optimization: Weight, diet, exercise, correction of vitamin deficiencies, and reducing alcohol, tobacco, or other substances.
Timed intercourse in the identified fertile window — conception is meant to happen naturally, in vivo.
What it deliberately excludes: In vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), and in its stricter NaProTechnology form, donor eggs or sperm and hormonal contraception — these exclusions are largely doctrinal, not based on effectiveness.
One caveat: “RRM” is an umbrella term, so the exact menu varies by clinic.
The charting-plus-diagnose-plus-treat core is consistent; how aggressively surgery, supplements, or immune/inflammatory treatments are used differs from one provider to the next.
Here is the part both sides skip. Some of RRM is just good medicine. Finding out why a couple cannot conceive before reaching for IVF is not a radical idea — it is what a careful doctor already does. Treating ovulation problems, correcting a thyroid, managing PCOS: that helps, and the evidence supports it. Even the new critical review agrees on that narrow point.
The trouble starts when RRM is sold as a match for IVF. Supporters point to big numbers. A 2008 study of 1,072 Irish couples — who had been trying for an average of 5.6 years, and a third of whom had already failed IVF — reported a cumulative live-birth rate near 53% over two years. A 2025 study from Spain of 1,310 couples reported a “take-home baby” rate of 35% counted plainly, rising to 62% after statistical adjustment. Those look impressive.
One word is missing from both: comparison. Neither study had a control group — no similar couples who got no RRM. That matters, because many couples with unexplained infertility eventually conceive on their own if you simply give them time. Without a comparison group, you cannot tell how many of those babies came from the treatment and how many would have arrived anyway. A “cumulative adjusted” rate with nothing to compare it to is a marketing figure, not proof.
This is exactly what the American Society for Reproductive Medicine found. In May 2026 its journal, Fertility and Sterility, published a six-part review of RRM and related practices. The lead systematic review found no high-quality evidence that RRM is as effective as IVF, and threw out many studies for weak design — above all, the missing control group. The same series was honest in the other direction too: for a few hormone and ovulation disorders, RRM-style treatment does work.
For patients, the real risk is time. Fertility falls with age, and it does not wait for a charting program to run its course. The Spanish study shows this in its own numbers: the take-home baby rate was 84% for women under 30, but only 24% for women over 40. A 38-year-old who spends a year charting instead of starting IVF is spending the one thing she cannot get back.
So here is my take. RRM’s core idea — diagnose the cause before you treat — is a fair criticism of clinics that jump to IVF without ever asking why a couple cannot conceive. I will say that plainly. But “diagnose first” is not a discovery; it is medicine. Selling RRM as a replacement for IVF is a different claim, and the evidence to back it does not exist. When NaProTechnology refuses IVF for every patient regardless of the diagnosis, that is a moral rule wearing a lab coat — doctrine, not data. Patients are free to choose it. They are not free to be misled about it.
Informed consent means telling that 38-year-old the truth. Try RRM if you want to. Fix what can be fixed. But know the numbers, know your age is on the clock, and know what a lost year can cost. That is not a pitch for IVF or against it. It is respect for the woman making the decision.
Bottom line: Restorative reproductive medicine is good medicine when it means finding and treating the cause of infertility.
It is oversold when it is pitched as an IVF replacement, because the evidence that it matches IVF is not there — and delay has a price.
References
1. Ganci D, et al. The effectiveness and safety of restorative reproductive medicine (RRM) compared to assisted reproductive technology or medically unassisted conception: a systematic review. Fertil Steril. 2026 (online ahead of print). Article ID S0015-0282(26)00192-5.
2. American Society for Reproductive Medicine. New research examines range of restorative reproductive medicine practices from evidence-based perspective [press release]. Washington, DC: ASRM; 2026 May 7.
3. Stanford JB, Parnell TA, Boyle PC. Outcomes from treatment of infertility with natural procreative technology in an Irish general practice. J Am Board Fam Med. 2008;21(5):375-384.
4. Natural procreative technology (NaProTechnology) for infertility: take-home baby rate and clinical outcomes in a 5-year single-center cohort of 1,310 couples. Front Reprod Health. 2025;7:1696679. doi:10.3389/frph.2025.1696679.